Introduction
There are unmistakable signs that oral cyclophosphamide (POCY) is on the verge of extinction in the management of autoimmune diseases through no fault of its own. This editorial discusses why we should not let this happen, and what we can do to prevent the untimely and arbitrary extinction of POCY. We begin by addressing the last point.
To avoid extinction, POCY must prove itself worthy by its performance in rigorous, prospective, randomized trials against its chief rivals, intravenous cyclophosphamide (IVCY) and mycophenolate (MMF). Unfortunately, there is resistance to include a POCY arm in clinical trials. A common concern is that POCY is 'too dangerous'. However, this concern is unwarranted. POCY toxicities can be reduced to that of MMF by limiting POCY dose and duration of therapy, as discussed later.
Some may argue that promoting cyclophosphamide therapy in any form is misguided. Instead, we should focus on developing therapies that are equally potent but safer and more targeted. Unfortunately, such therapy is not even on the horizon. The need to identify the gold standard immunosuppressant is particularly pressing for those of African ancestry who often respond less well to either IVCY or MMF than those of European ancestry [1] [2] [3] [4] . Defining the role of POCY takes on additional significance because of the current emphasis on comparativeeffectiveness studies [5] . As discussed later, compared to IVCY, POCY incurs much less cost and is easier for the patient.
To develop the case for POCY, we pose and answer a series of questions.
What Are the Signs of POCY's Imminent Demise as Acceptable Therapy for Severe SLE Nephritis?
Two recent editorials on the status of lupus nephritis therapy do not even mention POCY [6, 7] . In the most recent meta-analysis comparing MMF and cyclophosphamide therapy in SLE, POCY is mentioned but only to dismiss it because in the randomized trials POCY was used in only 52/456 (11.4%) of the patients. The rest received IVCY [8] . In addition, none of the recent or current multicenter SLE trials (EXPLORER, ALMS, LUNAR, BELONG, APRIL, or ACCESS) include a POCY arm.
With respect to the use of POCY in ANCA-related vasculitis, the future is also discouraging. CYCLOPS, the recently published randomized trial of IVCY versus POCY, concluded that POCY and IVCY provided similar outcomes but IVCY caused fewer episodes of leukopenia. This conclusion, which tilted the playing field in favor of IVCY, was surprising given the trends favoring POCY with regard to ESRD events, preservation of GFR, and relapse rate [9] . Indeed, if the data are made available on trends in proteinuria (proteinuria likely was lower in the POCY cohort because relapse rate was less) and the uncensored trend in eGFR is provided (they censored the GFR trend lines for those who reached ESRD-5 in the IVCY group and only 1 in the POCY group), the conclusion of that work might be changed to favoring POCY over IVCY, as we have suggested [10] . Although IVCY has reigned as the gold standard [11] , it did not acquire its golden reputation in rigorous head-tohead competition [12] . Indeed, until the recently reported EULAR study [13] (discussed later) there had been only one prospective randomized trial comparing IVCY to POCY in lupus. That study conducted by the NIH SLE group, showed no significant difference in outcome between the patients assigned to IVCY (n = 20) or POCY (n = 18), except that 3 in the POCY cohort developed cystitis. Thus, IVCY was chosen as the favored therapy [14] . However, the relevance of that trial to current practice is minimal because the regimens used (IVCY at 500-1,000 mg/m 2 /each 3 months for a median of 4 years, or POCY at 1-4 mg/kg/day for a median of 4 years) are far different from the IVCY and POCY regimens presently recommended.
Thereafter, the NIH SLE group studied only IVCY, comparing it to steroid therapy alone [15] [16] [17] [18] . It was over this period that the IVCY protocol evolved into its current form (500-750 mg/m 2 per month for 6 months, then quarterly IVCY for 12-18 months).
The NIH studies of cyclophosphamide therapy of SLE nephritis are landmarks because they establish beyond doubt the importance of immunosuppressive therapy for severe SLE GN. However, those studies do not constitute the basis for deciding the merits of POCY versus IVCY in the therapy of severe SLE GN. The recent EULAR study: 'pulse' cyclophosphamide versus 'continuous' cyclophosphamide in severe SLE nephritis [13] , also does not decide the merits of POCY versus IVCY. EULAR found no difference in outcome between the regimens. However, confounding the EULAR interpretation is that the pulse group received about 1/3 more cyclophosphamide than the continuous group. Thus, a plausible interpretation of EULAR is that POCY outperformed pulse therapy because it provided a similar outcome with less cyclophosphamide.
POCY can be expected to be more effective than IVCY because during the induction period, which is likely the most critical interval, the standard POCY regimen provides cyclophosphamide at about a 3-fold greater rate than the standard NIH IVCY protocol. Cyclophosphamide is virtually 100% absorbed from the gastrointestinal tract [19] . Thus, POCY and IVCY doses can be compared directly.
We suggest that the numerous reports of failure of cyclophosphamide to stop progression of SLE GN [1, 20] represent undertreatment because IVCY was used rather than POCY.
What about the Toxicity of POCY Compared to That of IVCY?
Given the difference in cyclophosphamide exposure between the POCY and IVCY regimens it can be readily understood that POCY might have greater toxicity than IVCY. However, as we recently reported [21] , the Hebert 
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Nephron Clin Pract 2011;117:c8-c14 c10 potential for greater toxicity with POCY than IVCY should be largely avoidable by lower dose, shorter course POCY along with measures for gonadal and bladder protection (discussed later). In addition, the POCY should be reserved for those presenting with severe SLE GN or those experiencing severe relapse of SLE GN. POCY is not recommended for maintenance therapy, even in low dose.
Another 'toxicity' is cost. POCY therapy is far less expensive than IVCY (in the United States less than USD 1,000 per course for POCY versus more than USD 9,000 per course for IVCY), and is more convenient. The greater cost and inconvenience of IVCY is incurred because in the USA, UK, and certain other countries, IVCY requires administration in an infusion center and incurs physician charges. A hidden expense is that with each infusion the patient loses a day of work, and sometimes more if lingering symptoms develop [21] .
IVCY also has unique toxicities and, although rare, can be severe. They include acute pulmonary failure (cyclophosphamide pneumonitis), and acute bone marrow failure [19] . Also, the risk of cyclophosphamide overdose in those with decreased GFR is greater with IVCY than POCY because only the POCY regimen allows daily dose adjustment. Unrecognized decreases in GFR is particularly a problem in young females whose serum creatinine does not reflect their GFR because of low creatinine production [22, 23] or because of increased tubular secretion of creatinine associated with low serum albumin levels [24] . Another concern is when the patient receives IVCY in error. This occurs when the acutely ill SLE patient receives IVCY on the assumption that severe SLE is present, when the real problem is severe infection. Disastrous consequences can follow [pers. unpubl. obs.].
What Is the Evidence that POCY May Be Better than MMF for Severe SLE Nephritis?
In the only prospective randomized trial comparing POCY to MMF, the therapies were comparable in remission induction rates but the relapse rate was 46% in the MMF group and only 17% in the POCY group (p = 0.02) (reviewed in [25] ). With regard to the greater toxicity of POCY than MMF noted in that study, we suggest that 6 months of POCY at 2.5 mg/d is more POCY than is needed. It exposes the SLE patient to risk without benefit [21] .
A relevant example of administering more cyclophosphamide than is needed is provided by the long-term follow-up of Houssiau's Euro-Lupus randomized trial of standard (NIH) IVCY protocol versus a low-dose IVCY protocol [26] . There was no benefit of the high-dose protocol. It only increased risk because of greater exposure to cyclophosphamide.
With regard to MMF versus IVCY in SLE nephritis, as we [27] and others [8] have recently discussed, there is a virtual tie with regard to safety and efficacy.
Should Cyclosporine or Tacrolimus Be Invited to Compete with POCY?
We suggest that calcineurin inhibitors (CNI) should not be used as the sole immunosuppressant for induction therapy in severe SLE GN. The rationale is that what has been interpreted as efficacy of CNI in SLE GN, and in other immune complex-mediated glomerulopathies, may only reflect the ability of this class of drugs to reduce proteinuria by stabilizing podocytes [28] . The underlying mechanism of the GN, immune complex accumulation, may not be affected by CNI [29] . The key details of this interpretation are as follows: (1) Proteinuria decreases rapidly when CNI are administered to patients with SLE GN. For example, in the patients assigned to CNI, proteinuria is significantly reduced by 4 weeks [30] or less [31] of CNI therapy. By contrast, in the patients assigned to azathioprine [31] or IVCY [30] , proteinuria is not significantly reduced until 3 months of therapy [30, 31] . The rapid onset of the proteinuria reduction with CNI is consistent with the notion that the proteinuria reduction is hemodynamic in origin, related to ability of CNI to stabilize podocytes [29] , or both. (2) Proteinuria increases rapidly when the CNI is discontinued in SLE GN. For example, in the largest randomized trial involving CNI versus IVCY in SLE GN, 40% of patients assigned to CNI experienced relapse of nephrotic syndrome within 9 months of stopping the CNI. By contrast, none of the patients assigned to IVCY experienced relapse by 9 months [32] . Similar high rates of early relapse of nephrotic syndrome occur in patients with idiopathic membranous nephropathy treated with CNI (reviewed in [33] ). This is consistent with the notion that the proteinuria reduction seen with CNI therapy is primarily related to CNI's hemodynamic/podocyte effect and, therefore, relatively rapidly reversible. By contrast, IVCY induces durable remissions because the nephritic process itself was controlled (i.e. the glomerular deposits tend to be eradicated [34] ). [37] ). Kidney function: serum creatinine, urinalysis with sediment exam at time of each physician monitoring (see below), and 24-hour urine for creatinine, protein, sodium, urea, potassium (if serum potassium abnormal) at baseline and at 4, 8, and 12 weeks during induction phase. Assess proteinuria from protein/creatinine (P/C) ratio of the intended 24-hour urine. Assess diet compliance from urine Na, K, and urea (discussed in [38] Maintenance phase (to maintain remission) Drugs Azathioprine 1.5-2.0 mg/kg IBW (maximum 150 mg/day) OR Mycophenolate mofetil (MMF) (maximum 1,000 mg twice daily). Usual dose 1,500-2,000 mg in divided doses. If low serum albumin, higher dose MMF is appropriate (discussed in [39] ). Consider cyclosporin if patient intolerant to azathioprine or MMF. Prednisone: week 12-13 (17.5 mg/day); week 13-14 (15 mg/day); week 14-15 (12.5 mg/day); week 15-16 (10 mg/day); week 16 and thereafter (IBW <70 kg: 7.5 mg/day; IBW >70 kg: 10 mg/day). Optimum duration of immunosuppressive therapy has not been rigorously studied. Experience suggests that maintenance immunosuppression should be maintained for at least 1 year after complete remission is achieved. Tapering of immunosuppression can then begin. More than 5 years of immunosuppressive therapy is needed in most of those who experience severe SLE GN (reviewed in [26] ). More than 10 years of immunosuppressive therapy is common in many of these patients (reviewed in [26] ).
Monitoring
Laboratory: CBC + differential count + platelet count, comprehensive metabolic profile, C3, 24-hour urine for protein, creatinine, urea, sodium, urinalysis. Complete remission is P/C ratio <0.3. C3 should return to normal. Microscopic hematuria may be present for a year or more. The most reliable measure of successful therapy is remission of proteinuria. Physician monitoring: usually each 2 months. Emphasis on kidney and CV protective therapy.
Adjunctive therapy (to be started at baseline) Kidney and cardiovascular protective therapy: blood pressure and diet control; ACE inhibitor/ARB therapy, statin/fibrate (discussed in [23, 35] ), hydroxychloroquine for anti-inflammatory and antithrombotic effects. 1 Gonadal protection: women: leuprolide 3.75 mg i.m. every 4-6 weeks for the duration of cyclophosphamide therapy; men: testosterone 100 mg i.m. every 2 weeks for the duration of cyclophosphamide therapy. Leuprolide and testosterone should be started about 1-2 weeks before exposure to cyclophosphamide. Initially, these hormones stimulate the ovaries and testes, making them more vulnerable to the effects of the alkylating agent. In situations where delay of cyclophosphamide is not advisable we suggest giving the initial dose of cyclophosphamide i.v., and beginning hormonal therapy 3 days later. By this time 15 cyclophosphamide half-lives will have elapsed. If the patient is to receive oral cyclophosphamide it can be started 3-4 weeks after the initial dose of intravenous cyclophosphamide was administered. c12 (3) Documentation that CNI therapy reduces proteinuria without eradicating glomerular immune deposits is provided by re-biopsy study in patients with idiopathic membranous nephropathy treated one year or more with cyclosporine. These patients experienced reductions in proteinuria; however, re-biopsy showed that the glomerular accumulation of immune deposits had not decreased. Indeed, generally the deposits were increased [29] . Nevertheless, we suggest that chronic CNI in low dose may have a role in maintenance therapy of SLE GN as reported by Moroni et al. [22, 31] .
What Is the Optimal POCY Regimen?
For SLE, we recommend a POCY regimen that is low dose (1.0-1.5 mg/kg ideal body weight) and short course (2-4 months depending upon patient response by 2 months of therapy), concomitant prednisone therapy, and measures for gonadal and bladder protection [21] . We also recommend measures that are kidney and cardiovascular protective [23, 35] . With these approaches, we have consistently achieved remission rates comparable to IVCY or MMF, and with a side effect profile equivalent to MMF [21] . Importantly, the only patients who progressed to ESRD were the few who were blatantly noncompliant with their drug regimen. Also, we found that African-Americans responded as well to POCY as European-Americans [21] . The recent major clinical trials found that African-Americans responded less well to IVCY than to MMF (reviewed in [21] ). This suggests that in African-Americans, POCY is superior to IVCY. The details of our recommended regimen for severe SLE GN are provided in table 1 .
In summary, the POCY regimen deserves to compete head-to-head with other immunosuppressive regimens to identify the best available immunosuppressant for SLE nephritis, and ANCA-related vasculitis.
Mark Twain once said ' the reports of my death have been greatly exaggerated '. This famous quotation might also to be applied to the report of Hebert and co-workers on the looming extinction of the use of oral cyclophosphamide in the treatment of severe lupus nephritis and other auto-immune diseases involving the kidneys. Actually, the application of short-term oral cyclophosphamide in the management of severe lupus nephritis is very much alive (although not necessarily thriving), at least in Columbus, Ohio; Chicago, Ill., and in many parts of the UK, Australasia and Europe. In my own practice, I have only used intravenous cyclophosphamide on one occasion in the past four decades. Hebert and friends bring to our attention, in a most forceful way, how weak the evidence is for superiority in both efficacy and safety of an intravenous cyclophosphamide regimen compared to a low-dose, short-term oral cyclophosphamide regimen in management of severe auto-immune renal disease. In
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Nephron Clin Pract 2011;117:c8-c14 c14 part, this is due to the paucity of head-to-head comparisons of efficacy in randomized clinical trials and the lack of clear-cut answers to the issue of comparative toxicity of the two regimens when cases are stratified according to a priori risk of treatment-induced complications. Lower cumulative dosage of cyclophosphamide in IV-based compared to oral-based regimens needs to be considered in the context of overall efficacy (remission, relapses, avoidance of ESRD), especially with long-term, followup, and the cumulative occurrence of adverse events (the burden of toxicity). Claims of preferential benefits of one regimen over the other in specific ancestral groups identified in post hoc analyses need to be confirmed in prospective randomized studies. The overall cost-effectiveness of measures to avoid bladder and gonad toxicity in either oral of IV-based regimens deserve careful scrutiny and testing. Nevertheless, the provocative essay by Hebert and colleagues should cause nephrologists to pause and ponder on how 'gold standard' therapies evolve and not rush to judgment in relegating reasonable treatment strategies to the 'trash bin' of history. Rather, ' He who refuses to learn deserves extinction ' (Rabbi Hillel).
